22
Participants
Start Date
May 31, 2010
Primary Completion Date
September 30, 2011
Study Completion Date
October 31, 2011
Oxazyme
"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
Mayo Clinic in Rochester, Rochester
Lead Sponsor
Collaborators (1)
OxThera
INDUSTRY
Mayo Clinic
OTHER